Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6868464 | 1.00 | MCHR1 (0.44) | MCHR1NPY5RADRA2ADRD2MAPK8 | |
| SCHEMBL6876612 | 0.88 | MCHR1 (0.46) | MCHR1NPY5RADRA2ADRD2MAPK8 | |
| SCHEMBL6455824 | 0.88 | MCHR1 (0.46) | MCHR1NPY5RADRA2ADRD2MAPK8 | |
| SCHEMBL6874708 | 0.85 | MCHR1 (0.42) | MCHR1NPY5RADRA2ADRD2MAPK8 | |
| SCHEMBL6873498 | 0.85 | MCHR1 (0.42) | MCHR1NPY5RADRA2ADRD2MAPK8 | |
| SCHEMBL6874714 | 0.85 | MCHR1 (0.42) | MCHR1NPY5RADRA2ADRD2MAPK8 | |
| SCHEMBL6873958 | 0.84 | HTR1A (0.47) | MCHR1NPY5RADRA2ADRD2MAPK8 | |
| SCHEMBL6877984 | 0.84 | MAPK8 (0.49) | MCHR1NPY5RADRA2AMAPK8MAPK9 | |
| SCHEMBL6873963 | 0.84 | HTR1A (0.47) | MCHR1NPY5RADRA2ADRD2MAPK8 | |
| SCHEMBL6877981 | 0.84 | MAPK8 (0.49) | MCHR1NPY5RADRA2AMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | claimed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MCHR1 2/4885NPY5R 8/4885ADRA2A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.